Method for selective oligonucleotide modification

US8936910B2 · kind B2 · utility

Assignee

• Antisense Pharma GmbH · DE

Inventors

• Andreas Mitsch · Lappersdorf, DE
• Karl-Hermann Schlingensiepen · Bovenden, DE
• Bernd Betzler · Aalen, DE
• Frank JASCHINSKI · Puchheim, DE
• Anneliese Schneider · Feldafing, DE

Key dates

• Filing date: Jun 10, 2011
• Grant date: Jan 20, 2015
• Expiry date: Jun 10, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/51
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Method for producing a modified oligonucleotide, wherein at least one polymer, preferably polyalkylene oxide, and/or a compound is covalently bound to the 5′-end or the 3′-end of the oligonucleotide via native ligation forming a native ligation site, with the proviso that the polymer and/or the compound is not a protein or peptide, if only the 5′-end of the oligonucleotide is modified by binding of the polymer or compound via native ligation. The invention is further directed to a modified oligonucleotide obtainable by the inventive method as well as the use of such modified oligonucleotide for the preparation of a medicament for preventing and/or treating a tumor, formation of metastasis, an immune disease or disorder, a cardiovascular disease or disorder, and/or a viral disease or disorder.